- Lead commercial negotiations with international tech transfer offices of class-leading medical science research institutes, leading to exclusive worldwide technology licensing agreements being awarded.- KLARO®, a novel in vivo surgical lighting device, officially launched for commercial sales & distribution at the MEDICA 2019 trade-fair in Dusseldorf, Germany and with FDA (USA), CE Mark (EU) & HSA (Singapore) approvals achieved. - Launched the ENLYT® portable endoscope system in 2024 for cancer screening and imaging of various nasopharyngeal conditions (e.g. dysphagia) in primary care settings.- Pioneering the ERES™ endoscopic robot, a groundbreaking add-on to any existing endoscope system on the market, conferring high-precision robotic capabilities to the user.Prizes, Awards & Recognitions:• WIPO Global Awards 2024 - Winners Trophy (Jul 2024)• Johnson & Johnson Innovation - JLABS Singapore Residency 2024 (May 2024)• MedTech Innovator APAC 2023 - Top 4 Grand Finalist (Dec 2023)• WIPO-IPOS IP for Innovation Awards 2022 - Winners Trophy (Sep 2023)Research & Commercialisation Grants:• Suzhou Industrial Park Tech Pioneer Award (Jan 2024)• A*STAR-Suzhou Industrial Park Technology Support Grant (Sep 2023)• Enterprise Singapore - Enterprise Development Grant (Innovation & Productivity) (Nov 2022)• Enterprise Singapore - Enterprise Development Grant (Core Capabilities) (Aug 2021)• A*STAR-SingHealth Medical Catalyst Programme (MedCaP) Grant (Sep 2019)• National Institutes of Health (USA) R01 Grant (Jul 2019)• National Health Innovation Centre (NHIC) - Innovation to Protect (I2P) Grant (Apr 2018)• Duke/Duke-NUS Collaboration Pilot Project Award (Feb 2016)• National Healthcare Innovation Centre (NHIC) Innovation to Develop (I2D) Grant (Oct 2015)

- VerImmune is advancing Anti-tumor Immune Redirection (AIR): A Breakthrough Therapy that Redirects Pre-Existing Immune Memory from Childhood Vaccination or Infection to Fight Cancer.

For TUV Rheinland Singapore and Malaysia.

- PathoVax is a new biotechnology start-up focused on the development of a universal Human Papillomavirus (HPV) vaccine to provide prophylaxis against all HPV-related cancers and diseases- Our pilot vaccine, RGVax, promises to provide protection against all 15 oncogenic HPVs and many others that cause various warts- Grants awarded: • NCI Grant for GMP manufacturing, toxicology & IND 2014 • Maryland Innovation Initiative Grant 2015- Awards & Prizes: • OneStart Americas' Top 10 Healthcare Startups of 2016 • 43North Business Plan Competition - Finalist 2016 • MassChallenge Boston - Finalist 2016 • Harvard Innovation Lab - Venture Incubation Program 2016

- Founding Director of Metropolitan Event Productions Pte Ltd and Metropolitan Concert Services Pte Ltd, co-managers of the Metropolitan Festival Orchestra (MFO).- First to pioneer the live movie-concert performance concept in Asia with the groundbreaking Asian premieres of The Lord of The Rings - The Fellowship of The Ring (2013) & The Two Towers (2014) movie-concert productions. - Special partner of INSEAD Business School for "Leadership through Performance - A Symphony in Collaboration" as part of the INSEAD MBA and Advanced Management Programme.

- Industry Mentor to the Duke-NUS Health Innovator Programme at the Office of Innovation and Entrepreneurship, Duke-NUS Medical School (National University of Singapore)- Mentee team (Team FemTech) went on to clinch 1st Place at the inaugural shark tank challenge of the DHIP programme, comprising judges from industry, government and academia

- Commercial research & development ongoing for a novel point-of-care saliva-based diagnostic kit for an endemic Asian tropical disease. - Awarded the ISO 113485:2016 Certification - Research Commercialisation Grants awarded: • SPRING-Agency for Science Technology & Research (A*STAR) - T-Up Grant 2015• SPRING Technology Enterprise Commercialisation Scheme (TECS) - Proof-of-Value (POV) Grant 2015- Awards & Prizes:• Finalist - TechVenture Start-Up Challenge 2015• 1st Runner Up Prize - Tech Plan Grand Prix 2015• Japan Tobacco Venture Prize - Tech Planter BioScience Grand Prix 2015

- Initiated Company’s corporate rebranding and operational restructuring- Led senior management through SPRING Singapore’s SMART-IMPACT Business Productivity Program, resulting in prominent featured articles in The Straits Times and Lianhe Zaobao (联合早报) national newspapers- Embarked Company on ISO 9001:2008 and 14001:2004 re-certification processes- Established joint-development program with Europe’s leading LED lighting manufacturer- Started initial discussions with Japan’s second largest lighting company that resulted in a USD 15M contract for LED lighting sales

- Mergers & Acquisitions and Structured Finance advisory- Debt restructuring- Capital raising for venture capital and private equity investments- Experienced in both buy- and sell-side mandates over a range of industries, including: Technology, F&B, Education, Consumer Entertainment, Manufacturing, Medical Devices and Clinical Diagnostics.

- Launched successful marketing sales of a magnetic interference cloud (MI Cloud) based consumer health product in November 2012- Responsible for exploring novel applications for the company's proprietary nanotechnology products in partnership with various international institutes of scientific research and higher learning- Company's breakthrough SleepEzy medical sleep-aid device conferred the prestigious "Most Innovative Product 2013" award by Guardian Pharmacy, Singapore's premiere pharmacy chain (151 stores)- SleepEzy was also conferred the "People's Choice Award 2013" (Top 21 Singaporean Brands) by My Paper (我报), one of Singapore's mainstream newspaper publications

- Chaired Asian investor meetings and managed capital raising in Asia as lead investor representative- Conducted ministerial-level discussions for 3 private hospital ventures in Vietnam with the country’s political elite

- Evaluated new medical science investment targets/initiatives conceived with and by Group Chairman Professor Sir Christopher Evans, OBE- Evaluated the Asian medical sciences commercial space for potential investment targets through meetings with stakeholders from academia, government and fund management sectors- Involved in buy-side meetings and discussions with brokers and senior management of target investment companies - Personal investor network in Asia include ultra-HNWIs, private banks and family offices

- Investigated novel nanoparticle-based delivery systems for cancer imaging and therapy

- Facilitated the running of medical device trials

- 1 of 30 PhD candidates chosen throughout Europe- Formulated a case solution as part of a 6-person team that was well-received by Engagement Managers

- Liaised closely with Partners and participated in the successful filing of patent submissions- Published a well-received legal commentary on patents and the pharmaceutical industry

- Developed investment recommendations to the Board through analysis of the local and global pre-clinical CRO industry- Assessed Singapore’s capabilities in cancer research through background studies and personal interviews with heads of private and public healthcare institutions- Offered a position as Industrial Analyst upon completion of internship

- Led negotiations leading to establishment of a 5-year manufacturing joint-venture contract with key lighting component businesses in 2 major Chinese cities.- Coordinated shipments of toolings and factory supplies for the company’s regional offices.- Identified new investment opportunities with CEO in emerging Chinese townships during invited government-level meetings.

- Performed competitor drug studies for the company’s proprietary Hepatitis drugs- Organised and scheduled clinical trials at the regional directors’ meetings as assistant to the Asia Pacific Medical Director- Developed a deeper understanding of the legalities behind the pharmaceutical industry, e.g. intellectual property and licensing matters